Indicators
Indicators
Value
Direction
MACD(12,26,9)
0.065
Buy
RSI(14)
58.401
Neutral
STOCH(KDJ)(9,3,3)
59.948
Neutral
ATR(14)
0.372
High Vlolatility
CCI(14)
89.958
Neutral
Williams %R
41.958
Buy
TRIX(12,20)
0.325
Sell
StochRSI(14)
37.978
Sell
Lifecore Biomedical Inc
LFCR8.170USD
+0.130+1.62%
Close 12/22, 16:00（ET）Quotes delayed by 15 min
306.10MMarket Cap
LossP/E TTM
TradingKey Stock Score
Overall Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
Peer Comparison
TradingKey Stock Score of Lifecore Biomedical Inc
Currency: USD Updated: 2025-12-22Key Insights
Lifecore Biomedical Inc's fundamentals are relatively stable, and its growth potential is high.Its valuation is considered fairly valued, ranking 69/158 in the Pharmaceuticals industry.Institutional ownership is very high.Over the past month, multiple analysts have rated it as Buy, with the highest price target at 8.75.In the medium term, the stock price is expected to trend up.The company has been performing well in the stock market over the past month, which is supported by its strong fundamentals and technicals.The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.
Lifecore Biomedical Inc's Score
Support & Resistance
Relevant data have not been disclosed by the company yet.
Score Analysis
Current score
Previous score
Analyst Rating
Based on
5
analysts
Buy
Current Rating
8.750
Target Price
+16.51%
Upside Space
Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.
Lifecore Biomedical Inc Highlights
StrengthsRisks
Lifecore Biomedical, Inc. is a fully integrated contract development and manufacturing organization (CDMO). The Company designs, develops, manufactures and sells differentiated products for biomaterials markets and license technology applications to partners. The Company offers highly differentiated capabilities in the development, fill and finish of sterile, injectable-grade pharmaceutical products in syringes and vials. It is involved in the manufacture of pharmaceutical-grade sodium hyaluronate (HA) in bulk form, as well as formulated and filled syringes and vials for injectable products used in treating a spectrum of medical conditions and procedures. The Company uses its fermentation process and aseptic formulation and filling expertise to develop HA-based products for multiple applications and to take advantage of non-HA devices and drug opportunities.
High Growth
The company's revenue has grown steadily over the past 3 years, averaging 24.79% year-on-year.
Turnaround to Loss
The company's performance has turned to a loss, with the latest annual loss of USD .
Undervalued
The company’s latest PE is -7.86, at a low 3-year percentile range.
Institutional Selling
The latest institutional holdings are 28.27M shares, decreasing 2.63% quarter-over-quarter.
Held by PRFDX
Star Investor PRFDX holds 2.60K shares of this stock.
Financial Health
Currency: USD Updated: 2025-12-22The current financial score of Lifecore Biomedical Inc is 7.76, ranking 97/158 in the Pharmaceuticals industry. Its financial status is weak, and its operating efficiency is high. Its latest quarterly revenue reached 31.11M, representing a year-over-year increase of 25.92%, while its net profit experienced a year-over-year increase of 32.76%.
Score
Financials
4.89
Key Metrics
Cash and cash equivalents
Total assets
Total liabilities
Free cash flow
Relevant data have not been disclosed by the company yet.
Quality of Earnings
6.76
Operational Efficiency
10.00
Growth Potential
9.66
Shareholder Returns
7.52
Lifecore Biomedical Inc's Company Valuation
Currency: USD Updated: 2025-12-22The current valuation score of Lifecore Biomedical Inc is 7.63, ranking 56/158 in the Pharmaceuticals industry. Its current P/E ratio is -7.86, which is -528.96% below the recent high of 33.71 and -103.95% above the recent low of -16.03.
Score
Valuation Dimensions
P/E
P/B
P/S
P/CF
Industry Ranking 69/158
Relevant data have not been disclosed by the company yet.
Earnings Forecast
Currency: USD Updated: 2025-12-22The current earnings forecast score of Lifecore Biomedical Inc is 7.20, ranking 113/158 in the Pharmaceuticals industry. The average price target for Lifecore Biomedical Inc is 8.75, with a high of 10.00 and a low of 7.50.
Score
Support & Resistance
Relevant data have not been disclosed by the company yet.
Analyst Rating
Based on
5
analysts
Buy
Current Rating
8.750
Target Price
+16.51%
Upside Space
Strong Buy
Buy
Hold
Sell
Strong Sell
Peer Comparison
171
Total
6
Median
8
Average
Company name
Ratings
Analysts
Lifecore Biomedical Inc
LFCR
5
Biogen Inc
BIIB
36
Amgen Inc
AMGN
35
Vertex Pharmaceuticals Inc
VRTX
33
Eli Lilly and Co
LLY
33
AbbVie Inc
ABBV
32
1
2
3
...
34
Financial Forecasting
EPS
Revenue
Net Profit
EBIT
Relevant data have not been disclosed by the company yet.
Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.
Price Momentum
Currency: USD Updated: 2025-12-22The current price momentum score of Lifecore Biomedical Inc is 7.40, ranking 73/158 in the Pharmaceuticals industry. Currently, the stock price is trading between the resistance level at 8.85 and the support level at 7.42, making it suitable for range-bound swing trading.
Score
Support & Resistance
Relevant data have not been disclosed by the company yet.
Indicators
The Indicators feature provides value and direction analysis for various instruments under a selection of technical indicators, together with a technical summary.
This feature includes nine of the commonly used technical indicators: MACD, RSI, KDJ, StochRSI, ATR, CCI, WR, TRIX and MA. You may also adjust the timeframe depending on your needs.
Please note that technical analysis is only part of investment reference, and there is no absolute standard for using numerical values to assess direction. The results are for reference only, and we are not responsible for the accuracy of the indicator calculations and summaries.
Moving Average
Indicators
Value
Direction
MA5
8.162
Buy
MA10
7.951
Buy
MA20
7.837
Buy
MA50
7.391
Buy
MA100
7.383
Buy
MA200
7.159
Buy
Institutional Confidence
Currency: USD Updated: 2025-12-22The current institutional shareholding score of Lifecore Biomedical Inc is 7.00, ranking 44/158 in the Pharmaceuticals industry. The latest institutional shareholding proportion is 75.45%, representing a quarter-over-quarter increase of 2.11%. The largest institutional shareholder is The Vanguard, holding a total of 1.62M shares, representing 4.33% of shares outstanding, with 3.69% increase in holdings.
Score
Institutional Shareholding
Relevant data have not been disclosed by the company yet.
Shareholder Activity
Name
Shares Held
Chg %
Wynnefield Capital, Inc.
Legion Partners Asset Management, LLC
Greenhaven Road Investment Management, L.P.
325 Capital LLC
Laughing Water Capital, LP
David Capital Partners, LLC
BlackRock Institutional Trust Company, N.A.
Geode Capital Management, L.L.C.
GrizzlyRock Capital, LLC
1
2
Risk Assessment
Currency: USD Updated: 2025-12-22The current risk assessment score of Lifecore Biomedical Inc is 4.03, ranking 93/158 in the Pharmaceuticals industry. The company's beta value is 0.60. This indicates that the stock tends to underperform the index during upward trending markets but experiences smaller declines during downward trending markets.
Score
Beta vs S&P 500 index
0.60
VaR
+4.96%
240-Day Maximum Drawdown
+29.17%
240-Day Volatility
+61.35%
Return
Best Daily Return
60 days
+9.86%
120 days
+10.84%
5 years
+85.63%
Worst Daily Return
60 days
-4.64%
120 days
-10.70%
5 years
-67.32%
Sharpe Ratio
60 days
+1.90
120 days
+0.36
5 years
+0.32
Risk Assessment
Maximum Drawdown
240 days
+29.17%
3 years
+73.19%
5 years
+86.93%
Return-to-Drawdown Ratio
240 days
+1.31
3 years
+0.14
5 years
-0.07
Skewness
240 days
-0.27
3 years
+2.44
5 years
+2.75
Volatility
Realised Volatility
240 days
+61.35%
5 years
+71.40%
Standardised True Range
240 days
+4.36%
5 years
+4.84%
Downside Risk-Adjusted Return
120 days
+60.21%
240 days
+60.21%
Maximum Daily Upside Volatility
60 days
+42.50%
Maximum Daily Downside Volatility
60 days
+24.84%
Liquidity
Average Turnover Rate
60 days
+0.40%
120 days
+0.58%
5 years
--
Turnover Deviation
20 days
-52.28%
60 days
-35.61%
120 days
-7.09%
Peer Comparison
Pharmaceuticals
Lifecore Biomedical Inc
LFCR
7.11 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
Mirum Pharmaceuticals Inc
MIRM
8.84 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
Regeneron Pharmaceuticals Inc
REGN
8.76 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
Prestige Consumer Healthcare Inc
PBH
8.76 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
Gilead Sciences Inc
GILD
8.71 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
Catalyst Pharmaceuticals Inc
CPRX
8.63 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
View more
FAQs
How does TradingKey generate the Stock Score of Lifecore Biomedical Inc?
The TradingKey Stock Score provides a comprehensive assessment of Lifecore Biomedical Inc based on 34 indicators derived from over 100 underlying data points. These indicators are categorised into six key dimensions: financial health, company profile, earnings forecasts, price momentum, institutional confidence, and risk assessment, collectively providing investors with a thorough analysis of Lifecore Biomedical Inc’s performance and outlook.
How do we generate the financial health score of Lifecore Biomedical Inc?
To generate the financial health score of Lifecore Biomedical Inc, we analyse various key financial indicators across several core dimensions, including financial fundamentals, earnings quality, operational efficiency, growth potential, and shareholder returns. By integrating these comprehensive data, the financial health score not only reflects Lifecore Biomedical Inc's overall stability, operational efficiency, and growth potential but also captures the investment returns delivered to shareholders. This score aims to support rational decision-making for investors and other stakeholders. A higher score indicates a better financial health of Lifecore Biomedical Inc.
How do we generate the company valuation score of Lifecore Biomedical Inc?
To generate the company valuation score of Lifecore Biomedical Inc, we use several key financial ratios, including P/E, P/B, P/S, and P/CF. These metrics compare Lifecore Biomedical Inc’s market value to its earnings, assets, sales, and cash flow, serving as core indicators for assessing company value. By analysing these ratios in an all-round manner, the valuation score reflects not only the market’s current perception of Lifecore Biomedical Inc’s value but also its future profitability and growth potential, thereby supporting more informed investment decisions. A higher score indicates a fairer valuation of Lifecore Biomedical Inc.
How do we generate the earnings forecast score of Lifecore Biomedical Inc?
To calculate the earnings forecast score of Lifecore Biomedical Inc, we consider various key indicators such as analyst ratings, financial forecasts, support and resistance levels, and peer comparisons:Current ratings and price targets directly reflect analysts’ expectations, while the upside space indicates their views on the stock’s growth potential.Financial metrics like earnings per share (EPS), revenue, net income, and earnings before interest and taxes (EBIT) are core measures for assessing profitability.By analysing the high, median, and low ranges of the target price, we can identify price trends and determine key support and resistance levels.Comparing these indicators against peers provides context for the stock’s performance and helps
anchor more realistic expectations.These factors together form a comprehensive earnings forecast score that accurately reflects the stock’s expected financial performance and growth potential. A higher score suggests that analysts have a more optimistic outlook on Lifecore Biomedical Inc’s future.
How do we generate the price momentum score of Lifecore Biomedical Inc?
When generating the price momentum score for Lifecore Biomedical Inc, we examine momentum indicators including support and resistance levels as well as volume metrics.Support levels represent price points where buying interest is strong enough to prevent further declines, while resistance levels indicate prices where selling pressure may hinder upward movement. By analysing typical price volume alongside total volume, we assess overall market activity and liquidity. These indicators help identify price trends and potential shifts, enabling more accurate predictions of future earnings.This comprehensive approach can reflect market sentiment and enable rational forecasts of Lifecore Biomedical Inc’s prices. A higher score indicates a more stable short-term price trend for Lifecore Biomedical Inc.
How do we generate the institutional confidence score of Lifecore Biomedical Inc?
To generate the institutional confidence score of Lifecore Biomedical Inc, we analyse both the proportion of shares held by institutions and the number of shares they own. A higher institutional ownership percentage indicates strong confidence of professional investors, which is generally a positive signal about Lifecore Biomedical Inc’s potential. By examining the number of shares held, we gain deeper insight into institutions’ commitment and attitude toward the stock, as institutional investors typically conduct thorough analysis before making investment decisions. Understanding institutional confidence helps us refine earnings forecasts and provides a more reliable perspective on the company’s future performance and market stability. A higher score indicates greater institutional endorsement of Lifecore Biomedical Inc.
How do we generate the risk management score of Lifecore Biomedical Inc?
To assess the risk management score of Lifecore Biomedical Inc, we examine multiple key indicators related to returns, risk, volatility, and liquidity.The highest and lowest daily returns reflect the potential size of gains and losses, while the Sharpe ratio measures risk-adjusted return performance. On the risk side, we analyse maximum drawdown and the return-to-drawdown ratio to identify extreme loss scenarios. Skewness helps assess the distribution of returns and whether performance may be biased. Volatility indicators—such as realised volatility and standardised true range—reveal price fluctuations. Downside risk-adjusted returns provide insight into potential losses and gains. Lastly, liquidity metrics like average turnover rate and turnover deviation indicate how actively the stock is traded.These indicators together provide a multi-dimensional understanding of Lifecore Biomedical Inc’s risk-return profile, serving as core factors of the risk management score. A higher score indicates lower risk on the side of Lifecore Biomedical Inc.
